key: cord-0784789-ntiss6sv authors: Jenei, Tímea; Jenei, Sándor; Tamás, László T.; Putics, Ákos; Knausz, Márta; Hegedüs, Irén; Dinnyés, Imre; Szalai, Zsuzsanna; Molnár, Tamás F.; Büki, Béla title: COVID-19 mortality is associated with low Vitamin D levels in patients with risk factors and/or advanced age date: 2021-11-24 journal: Clin Nutr ESPEN DOI: 10.1016/j.clnesp.2021.11.025 sha: 26652916a443fd211c53aa7e1724c4d1fd2fc6e5 doc_id: 784789 cord_uid: ntiss6sv BACKGROUND & AIMS Although conclusive evodence is yet lacking, it has been suggested that vitamin D deficiency (VD) may be associated with a more severe course of SARS-CoV-2 Infection (COVID-19). In this retrospective study we assessed the association of VD deficiency with mortality in a group of COVID-19 patients treated in a tertiary referral center. METHODS Data of 257 Covid-19 patients hospitalized between 30th September 2020 and 2nd March 2021 have been collected retrospectively. The following parameters were collected: age, gender, serum level of 25-OH-Vitamin D3, outcome (survival/death) comorbidities (cancer, diabetes mellitus and chronic obstructive pulmonary disease). Serum VD measurement was done within 3 days of admission. RESULTS VD levels were significantly lower in patients who did not survive, however, in this patients’ group the average age was significantly higher than among those, who survived. After age-matching, in a subgroup of patients with risk factors and/or 60 years of age or older who survived had significantly higher VD level in their serum than those who deceased. Serum C-reactive protein, lactate-dehydrogenase and creatinin-kinase were significantly higher in the group in which the patients died, however these laboratory parameters did not correlate with the VD levels. CONCLUSION We found that in COVID-19 infection, when old age as risk factor (60 years of age or older) was pooled with risk factors (cancer, diabetes and/or COPD), the VD levels were significantly lower in the patient group, in which the patients did not survive. We suggest further, prospective studies in similar subgroups to explore a possible causal relationship. Since vitamin D (VD) supplementation of 400-1000IU/day seems to have a modest protective effect for acute respiratory infections (1), it has been suggested that VD deficiency may be associated with a more severe course of SARS-CoV-2 Infection (COVID-19) (2) . In a recent review (3) the authors concluded that high-quality evidence is currently lacking, but there is suggestive evidence for an immunomodulatory role of vitamin D for respiratory infections and contextual evidence of the shared risk factors between vitamin D deficiency and COVID-19 infection outcome: older age, obesity, and minority ethnicity. It has been shown that airway diseases are associated with dysregulated vitamin D metabolism, raising the possibility that vitamin D deficiency might arise because of pulmonary inflammation (4) and the results of studies on low pre-pandemic 25(OH)D levels and subsequent incidence and severity of COVID-19 were conflicting (5, 6) . In this retrospective study we assessed the association of VD deficiency with mortality in a group of COVID-19 patients treated in a tertiary referral center. In Figure 1 . We show the VD levels according to age in all patients, with or without risk factors and in Table 1 we list the main statistical results. We carried out several subgroup analyses in order to examine eventual differences in VD levels according to age under or over 60 years and risk factors. VD levels were significantly lower in patients who did not survive and were 60 years of age or older, however, in this patients' group the average age was significantly higher than among those, who survived. In the younger patients' groups (under 60 years of age) there was no significant difference in VD levels between the groups created according to survival. As a next analysis, matched groups were built ('recovered versus deceased') considering old age in itself as risk factor by including patients with risk factors and/or patients who were 60 years or older (with or without risk factors). Age-matching was done by randomly including a patient with the same age into the group of recovered patient for every patient in the deceased group. Then the VD serum level was compared between groups. The J o u r n a l P r e -p r o o f results are shown in Table 2 . The patients with risk factors and/or 60 years of age or older who survived had significantly higher VD level in their serum than those who deceased. Patients with risk factors and/or 60 years of age or older VD-level recovered (mmol/L) 30 ± 12 ***(n=65) VD-level deceased (mmol/L) 21 ± 13 (n=65) Age recovered all cases (mean age in years ± SD) 76 ± 9 Age deceased all cases (mean age in years ± SD) 77± 10 Our results show that summary mortality statistics including all hospitalized patients tend to obscure differences of pre-infection VD status between subgroups 'survived/died', because VD levels tend to be lower in elderly patients or in patients with other risk factors, who also are dying of the infection more frequently. Moreover, a subgroup analysis showed that among patients younger than 60 years of age with or without risk factors there was no difference in VD level between surviving or deceased patients. However, when old age (60 years of age or older) was pooled with risk factors (cancer, diabetes and/or COPD), the VD levels were significantly lower in the patient group, in which the patients did not survive. Although there is an abundance of papers on the potential connection between VD-deficiency and poor survival in COVID-19 in literature, the existence of such a connection has not been proven conclusively. According to several more recent publications in which higher case numbers have been examined, VD insufficiency or deficiency was also not independently associated with either (9), therefore we supply data as supplemental material summarizing inflammatory laboratory parameters in the two groups. Serum C-reactive protein, lactate-dehydrogenase and creatinin-kinase were significantly higher in the group in which the patients died; D-dimer, troponin, ferritin, procalcitonin and lymphocyte counts were not different between the two groups. We carried out a correlation analysis between serum VD-level and CRP, CK and LDH, however these laboratory parameters did not correlate with the VD levels (suppl. material, Table 4 ). This means in our view that a simple relationship between inflammation and low VD levels could not be found. Based on our dataset, it cannot be decided if patients who did not survive had low VDlevels because of their advanced age and/or risk factors and they had a worse outcome independently of the VD status, or perhaps there exists a causal relationship. This issue may be examined by prospective studies in which VD substitution is given. We found that in COVID-19 infection, when old age (60 years of age or older) was pooled with risk factors (cancer, diabetes and/or COPD), the VD levels were significantly lower in the patient group, in which the patients did not survive. We suggest further, prospective studies in similar subgroups to explore a possible causal relationship. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors Vitamin D supplementation to prevent acute respiratory infections: a systematic review and metaanalysis of aggregate data from randomised controlled trials Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis Vitamin D and covid-19 Vitamin D Metabolism Is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study Vitamin D concentrations and COVID-19 infection in UK Biobank Genetically predicted serum vitamin D and COVID-19: a Mendelian randomisation study Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients Vitamin D: A magic bullet or a myth? The authors do not declare any conflicts of interest